Someone please explain thisIf the primary endpoint was 43% reduction in mortality why would the DSMB continue the trial at the first and second interim analysis if it didn't meet at least 43% at those pointsTo me it looks like the 3rd interim analysis had a reduced mortality of less than 43% which would make achieving the endpoint impossible so it ended for further review.
the DSMB said it didn't believe the endpoints will be reached (obviously of any one of the interim analysis had less than a 43% reduction in mortality)
it didn't state the trial ended for futility explicitly
Novartis deal on the rocks, page-60
-
- There are more pages in this discussion • 188 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.028(2.31%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $5.546M | 4.717M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 82767 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 52419 | 16 |
View Market Depth
| Last trade - 15.51pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |